key: cord-1042236-1bzv5rhp
authors: Vogt, Anne-Cathrine S.; Jörg, Lukas; Martina, Byron; Krenger, Pascal S.; Chang, Xinyue; Zeltins, Andris; Vogel, Monique; Mohsen, Mona O.; Bachmann, Martin F.
title: Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies
date: 2021-12-22
journal: bioRxiv
DOI: 10.1101/2021.12.20.473421
sha: b93a3feed1288a50697bc258f80314f4adfd807f
doc_id: 1042236
cord_uid: 1bzv5rhp

mRNA based vaccines against COVID-19 have proven most successful at keeping the SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody response for the control of continuously emerging SARS-CoV-2 variants of concern (VoCs) and to overcome other obstacles such as supply shortage, costs and reduced safety issues or inadequate induced immune-response. In this study, we investigate the antibody responses induced by heterologous prime-boost with vaccines based on mRNA and virus-like particles (VLPs). The VLP-based mCuMVTT-RBM vaccine candidate and the approved mRNA-1273 vaccine were used for this purpose. We find that homologous prime boost regimens with either mRNA or VLP induced high levels of high avidity antibodies. Optimal antibody responses were, however, induced by heterologous regimens both for priming with mRNA and boosting with VLP and vice versa, priming with VLP and boosting with mRNA. Thus, heterologous prime boost strategies may be able to optimize efficacy and economics of novel vaccine strategies.

Multiple immunizations are usually required for most vaccines to be successful in 45 protecting against a virus and its emerging variants. For instance, five-dose series of Tetanus, 46 Pertussis and Diphtheria (DTaP) vaccine is required during childhood and an adolescent 47 booster dose to elucidate the aimed protection (1). It is not entirely clear why some vaccines 48 require more additional boosters than others; however, it is well accepted that multiple 49 immunizations are essentials for better response, in particular for non-replicating vaccines (2). 50 An annual dose of influenza vaccine is also recommended for persons who may be at 51 increased risk for complications from influenza infections.

Additionally, heterologous prime-boost regimens in particular when using vectored 53 vaccines have previously shown better immunogenicity; for example, priming with e.g. DNA 54 and boosting with e.g. viral vectors (3, 4). The need to change the vector may be explained 3 55 by the induction of neutralizing antibodies against the vector, which compromise further 56 boosting with the same vector. Vaccine-specific antibodies have also been reported to 57 suppress the cytotoxic (CTL) response when using the non-infectious virus-like particles 58 (VLPs) derived from human papilloma virus (HPV) or Q-p33 for immunization (5, 6). 222 We have previously hypothesized that natural infection with SARS-CoV-2 virus induces short-223 lived neutralizing antibodies due to the unusually large distance between RBD-epitopes 224 embedded in the membrane surface (28). This obstacle may be overcome by grafting RBM or 225 RBD onto highly repetitive nanoparticles such as the here used mCuMV TT VLPs, resulting in 226 successful display of the virus-epitopes at optimal distances of 5-10nm. This pathogen-227 associated structural pattern (PASP) may also play a role in the induction of higher avidity 228 antibodies as shown after the 2 nd booster dose.

With the continuous emergence of SARS-CoV-2 variants (VoCs), it may be essential 230 to administer repetitive booster doses, as higher antibody levels may need to be maintained 231 for sustained protection. Indeed, our data demonstrate that a 2 nd boost can maintain antibody 232 titers. Furthermore, the 2 nd boost in the different heterologous regimens in groups II, III and IV 

The traditional vaccine platforms have shown 84 lower incidence of adverse side effects (14); however they typically also showed inferior 85 immunogenicity in comparison to the next-generation mRNA vaccines

boost vaccination strategies using different 87 vectors should be tested to elicit broader and more efficient protective immune-responses with 88 better and improved safety profiles. This strategy may meet the emergency needs in the 89 current pandemic. In the current study, we evaluated different prime and boost regimens 90 combining mRNA-1273 with a VLP-based vaccine based, namely mCuMV TT -RBM. We have 91 previously designed and developed the scalable and immunogenic VLP-based COVID-19 92 vaccine mCuMV TT -RBM, which has been shown to induce RBD-specific IgG and IgA 93 antibodies with strong neutralizing capability

We show that a booster dose with mRNA-1273 or mCuMV TT -RBM induced high levels of high 95 avidity antibodies. Interestingly, highest antibody responses were measured, when 96 vaccination was performed by heterologous administration of mRNA for prime and VLP as 97 boost and vice versa, priming with VLP and boosting with mRNA. Along these findings, 98 heterologous prime boost strategies may be able to improve efficacy and economics of current

Moderna  ) and our newly developed mosaic COVID-19 VLPs-based vaccine mCuMV TT -RBM 107 (15) as illustrated in Figure 1A. For SARS-CoV-2 specific vaccine, the mRNA provides the 108 genetic expression of the spike protein of COVID-19 (17). The mRNA of the spike protein is 109 then translated by the host, thus allowing the host to mount an antibody response against the 110 expressed protein (18, 19)

at least for the original Wuhan strain (10). mCuMV TT -RBM is a plant-112 derived VLPs which incorporates the receptor-binding motif (RBM) of SARS-CoV-2 using 113 genetic fusion techniques. mCuMV TT -RBM also incorporates in its interior surface a tetanus 114 toxin (TT) epitope which is believed to enhance the immune response in elderly people

TT-epitope is expected to augment the interaction between TT-specific T 116 helper (T H ) cells and RMB-specific B cells. This is supported by the fact that pre-existing 117 immunity to the chosen TT epitope is very broad in humans (and animals) as the peptide binds 118 essentially to all HLA-DR molecules and most people have been immunized many times 119 against TT. Additionally, mCuMV TT -RBM is packaged with ssRNA

Balb/c mice were divided into two groups for 123 subcutaneous (s.c.) priming with mRNA-1723 or mCuMV TT -RBM vaccines (Fig. 1A). Blood ELISA. Our results showed successful induction of RBD-specific antibodies 7 days after 126 subcutaneous injection of mRNA-1723 or mCuMV TT -RBM (Fig. 1B). mRNA-1723 was 6 127 superior to mCuMV TT -RBM in inducing RBD-specific antibodies measured on days

The primed mice were divided next into four groups (Fig. 1A) and received a booster 130 dose on day 21 using mRNA-1723 or mCuMV TT -RBM. Therefore, mice are grouped and 131 immunized as follows: Group I (mRNA-1723  mRNA-1723

Blood samples were collected on days 28 and 35 to measure the 134 induced RBD-specific antibodies by ELISA. Interestingly, heterologous boost with mRNA-135 1723 or mCuMV TT -RBM showed a similar induction of RBD-specific antibodies with no 136 statistical difference for sera collected on days 28, 35 and 42 (Fig. 1H -K)

Taking into account the slightly inferior immunogenicity of mCuMV TT -RBM vaccine to mRNA-143 1723, and our previous data showing that a 2 nd booster dose of mCuMV TT -RBM would 144 enhance the quality of the induced antibodies (15), a 2 nd booster dose was performed on day 145 56 in Groups II, III and IV as illustrated in Figure 2A. As Group I represents the standard 146 immunization strategy followed in almost all countries, no booster dose was applied. ELISA 147 data for OD450 and OD50 for days 63 and 70 did not show an increase in RBD-specific 148

The avidity of the induced antibodies was assessed using a modified immunoassay

More specifically, 151 we compared the avidity of RBD-specific antibodies on days 42 and 70, i.e. after 2 or 3 152 injections. For group I, which was primed and boosted with mRNA-1723, the avidity of RBD-153 specific antibodies didn't differ on days 42 and 70 (p. 0.7460)

This finding was similar in group IV (which received a prime with 157 mCuMV TT -RBM, followed by a 1 st boost with mRNA-1723 and 2 nd boost with mCuMV TT -RBM), 158 again with statistically significant difference in avidity between day

The induction of higher avidity antibodies following 3 vaccinations with mCuMV TT -RBM is 160 consistent with our previous findings

Accordingly, we have tested RBD-specific 163 antibodies up to 5 months after the priming dose. The results revealed a slight drop in the 164 antibody titer in group I (received 2 doses of mRNA-1723), however was not significantly 165 different when compared to the other groups. Groups II

To test the capacity of the induced antibodies following the heterologous prime-boost regimen 171 to neutralize SARS-CoV-2 wild-type and its mutated delta variant, we used a reduction of 172 cytopathic effect (CPE) assay. 100 TCID 50 of SARS-CoV-2/ABSneutralization titer against SARS-CoV-2 wild-type (Fig.3A). When comparing the induced 176 neutralization titer against the delta VoC

039) confirming the superiority of mRNA only over VLP-178 only based vaccines. However, no statistical differences have been detected between Group 179 I and II (p. 0.2558) or between Group I and IV (p >0.999) (Fig. 3B). This indicates that mRNA 180 may be used to boost VLP-induced antibody responses; or vice versa, and probably more 181 importantly, VLPs may be used to boost RNA

distancing, contact tracing as well as isolation of sick or infected people are important but 189 insufficient measures to reduce the spread of the corona virus disease (23). Accordingly, 190 vaccine campaigns are needed to curb the spread of SARS-CoV-2 and thereby reducing the

According to 194 manufactures information, mRNA-1273 is stable up o 6 month when kept at -20°C, whereas 195 to store BNT162b2 for the same time-period, temperatures between -80°C to -60°C are 196 needed

This can cause a major problem in 202 low-income countries, to afford these types of vaccines. Therefore, cost effective and efficient 203 vaccine candidates are of high importance taking into account the continuous persistence of 204 the virus and the obstacles in eradicating it worldwide. We have previously shown high stability 205 of our newly developed VLP-based vaccine-candidate mCuMV TT -RBM which was stable for 206 at least 14 months at 4°C without signs of degradation (15)

Additionally, the production of mCuMV TT -RBM is highly scalable allowing the production of 210 millions of the doses in a single 1000L fermenter run (15). The rapid pace of mRNA vaccine 11

In vivo experiments were performed using 8-12 weeks-old female, BALB/cOlaHsd mice 255 purchased from Envigo

All animals could acclimatize to the facility

All animals were treated for experimentation according to protocols approved by the

Mosaic 264 (mCuMV TT -RBM) vaccine was prepared as previously described by

) using different regimens 267 as summarized in Table 1. 10g (Prime on day 0) and 10g for a booster dose on day 21 were 268 used. mCuMV TT -RBM vaccine and mRNA-1273 were diluted in 1xPBS in a final volume of 269 100l for final injection. Serum was collected on a weekly basis. The three doses regimen 270 (prime-1 st boost-2 nd boost) was either 10g prime and 100g 1 st and 2 nd boost or 100g prime 271 and 10g 1 st boost and 100mg 2

SARS-CoV-2 RBD wildtype , was cloned as a synthetic gene into pTWIST-CMV-BetaGlobin-278 WPRE-Neo vector (Twist Biosciences, CA, USA) and expressed in HEK293F cells through 279 the Expi293 system

To determine the total IgG antibodies against the vaccine mCuMV TT -RBM as well as mRNA-283 1273 in sera of vaccinated mice, ELISA plates (96 well half-area ELISA plates

Catalog # 3690) were coated with SARS-CoV-2 RBD (wildtype) at a concentration 285 of 1g/ml overnight at 4°C. ELISA plates were washed with PBS-0.01% Tween and blocked 286 using 100l PBS-Casein 0.15% for 2h in RT. Sera from vaccinated mice was serially diluted 287 1:3 starting with a dilution of 1:20 and incubated for 2h at RT. After washing with PBS-288 0.01%Tween, goat anti-mouse IgG conjugated to Horseradish Peroxidase (HRP) (Jackson 289 ImmunoResearch

stopped by adding equal 1 M 291 H2SO4 solution. OD450 was measured using the SpectraMax M5 ELISA reader (Molecular 292 Devices, Catalog # M5) and read at OD 450 nm or expressed as Log OD 50

To test IgG antibody avidity against RBD protein, threefold serial dilutions of 1/20 diluted mice 296 sera, were added to ELISA plates (96 well half-area ELISA plates

Catalog 297 # 3690) coated over night at 4°C with 1g/ml RBD. After incubation at RT for 1h, the plates 298 were washed once in PBS-0.01% Tween, and then washed 3x with 7M urea in PBS-299 0.05%Tween or with PBS-0.05% Tween for 5min every time. After washing with PBS-300 0.05%Tween, goat anti-mouse IgG conjugated to Horseradish Peroxidase (HRP) (Jackson 301 ImmunoResearch

To determine the neutralizing ability and capacity of vaccine induced antibodies a CPE assay 305 was performed using wild-type SARS-CoV-2 (SARS-CoV-2/ABS/NL20) and delta Strain

Two-fold serial dilutions were 307 prepared starting at 1:20 up to 1:160. 100 TCID 50 of the virus was added to each well and 308 incubated for 37°C for 1h. The mixture has been added on a monolayer of Vero cells and 309 incubated again for 37°C for 4 days. Four days later the cells were inspected for cytopathic 310 effect

All data are presented as mean ± SEM. Data were analyzed using Ordinary One-way ANOVA 313 for multiple comparisons and Students' t-test when comparing two groups. At least two 314 independent experiments were performed. Statistical significance was set at

Analyses were performed using GraphPad PRISM 9

Bachmann is a board member of Saiba AG and holds the patent of CuMV TT -VLPs. M

Mohsen received payments by Saiba AG to work on the development of vaccines. M. F

Design of experiments, acquisition of data, interpretation, 328 and analysis of data. ASV, MOM, MV, MFB: Writing, revision, and editing of manuscript

AZ: Technical, material, and tool support. MOM and MFB: Study supervision. All authors

The datasets generated during and/or analyzed during the current study are available from

Prevention 339 of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations 340 of the Advisory Committee on Immunization Practices (ACIP)

Heterologous prime-boost vaccination

Effect of preexisting neutralizing 352 antibodies on the anti-tumor immune response induced by chimeric human papillomavirus 353 virus-like particle vaccines

Innate 355 signaling regulates cross-priming at the level of DC licensing and not antigen presentation

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Heterologous prime-boost: breaking 360 the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes 361 Infect

Efficacy and Safety 363 of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and 365 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

COVID-19 Vaccines: Current 367 Understanding on Immunogenicity, Safety, and Further Considerations

Virus-370 like particles: preparation, immunogenicity and their roles as nanovaccines and drug 371 nanocarriers

Major findings and recent 373 advances in virus-like particle (VLP)-based vaccines

A scalable and 377 highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. Allergy

Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor 380 Binding Motif (RBM) and Fusion Domain. Vaccines (Basel)

A Thermostable mRNA 382 Vaccine against COVID-19

Review the safety of Covid-19 mRNA vaccines: a review. Patient 384 Saf Surg

mRNA: From a chemical blueprint 386 for protein production to an off-the-shelf therapeutic

Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. Npj Vaccines

Incorporation of tetanus-392 epitope into virus-like particles achieves vaccine responses even in older recipients in models 393 of psoriasis, Alzheimer's and cat allergy

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and 399 Delta variant prevalence. medRxiv

Addressing 401 the Cold Reality of mRNA Vaccine Stability

COVID-19 vaccines: comparison 405 of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and 406 Moderna Vaccines

Stability studies of HIV-1 Pr55(gag)

virus-like particles made in insect cells after storage in various formulation media

SARS-CoV-2 structural 411 features may explain limited neutralizing-antibody responses

Vaccination regiment (Prime/Boost) D0/D21 and groups. B-D) OD 450 of RBD-specific IgG for 419 the groups vaccinated with mRNA-1723 or mCuMV TT -RBM

Log 10 OD 50 of RBD-specific IgG titers for the groups vaccinated with mRNA-1723 or mCuMV TT -421 RBM on days 7, 14 and 21. H-J) OD 450 of RBD-specific IgG for the groups boosted with mRNA-422 1723 or mCuMV TT -RBM on days 28, 35 and 42. K) Log 10 OD 50 of RBD-specific IgG titers for 423 the groups boosted with mRNA-1723 or mCuMV TT -RBM on days 28

Statistical analysis (mean ± SEM) using one-way ANOVA in K or Student's t test in

One representative of 3 similar experiments is shown. The value of p<0

Figure 2. A second booster dose further enhances the induced immune response 429 Enhanced immune response with second booster dose. A) Vaccination regiment (Prime-430 Boost-Boost) D0/D21/D56 and groups. B and C) OD 450 of RBD-specific IgG for the groups 431 vaccinated with mRNA-1723 or mCuMV TT -RBM

D and E) Log 10 OD 50 of RBD-specific IgG titers for the groups vaccinated with mRNA-433 1723 or mCuMV TT -RBM on 63 and 70 using D0/D21/D56 regimen. F) Avidity Index of RBD-434 specific IgG in mice vaccinated with mRNA-1723 or mCuMV TT

OD 450 of RBD-specific 436 longeivity IgG for the groups vaccinated with mRNA-1723 or mCuMV TT -RBM 5 months after 437 priming using D0/D21/D56 regimen. H) Log 10 OD 50 of RBD-specific IgG titers for the groups 438 vaccinated with mRNA-1723 or mCuMV TT -RBM 5 month after priming, using D0/D21/D56 439 regimen. Statistical analysis (mean ± SEM) using one-way ANOVA in D,E and H or Student's 440 t test in F

A and B) Neutralization titer (CPE) for sera 445 from mice vaccinated with mRNA-1723 and mice vaccinated with mCuMV TT -RBM, sera from 446 day 63 (after 2nd boost). Statistical analysis (mean ±SEM) using ANOVA